Privia Health Group, Inc. (NASDAQ:PRVA) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. cut its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 25.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 167,498 shares of the company’s stock after selling 56,744 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Privia Health Group were worth $3,857,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PRVA. Advisors Preferred LLC acquired a new stake in Privia Health Group in the fourth quarter valued at $2,137,000. International Assets Investment Management LLC increased its holdings in Privia Health Group by 2,721.7% during the 4th quarter. International Assets Investment Management LLC now owns 7,139 shares of the company’s stock valued at $164,000 after acquiring an additional 6,886 shares in the last quarter. Riverbridge Partners LLC increased its holdings in Privia Health Group by 8.7% during the 4th quarter. Riverbridge Partners LLC now owns 4,342,385 shares of the company’s stock valued at $100,005,000 after acquiring an additional 348,852 shares in the last quarter. Trust Point Inc. acquired a new position in Privia Health Group during the fourth quarter worth about $585,000. Finally, Bell Bank lifted its holdings in shares of Privia Health Group by 49.1% in the fourth quarter. Bell Bank now owns 27,758 shares of the company’s stock valued at $639,000 after purchasing an additional 9,143 shares in the last quarter. 94.48% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently weighed in on PRVA shares. Bank of America cut shares of Privia Health Group from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $27.00 to $21.00 in a research note on Thursday, February 22nd. UBS Group dropped their price target on Privia Health Group from $31.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, March 1st. Jefferies Financial Group began coverage on Privia Health Group in a research report on Monday, February 26th. They issued a “buy” rating and a $25.00 price objective on the stock. JPMorgan Chase & Co. decreased their price objective on Privia Health Group from $38.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 6th. Finally, Barclays initiated coverage on shares of Privia Health Group in a report on Wednesday, March 6th. They set an “equal weight” rating and a $22.00 price target for the company. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $28.18.

Privia Health Group Price Performance

Shares of PRVA opened at $17.69 on Wednesday. Privia Health Group, Inc. has a 12 month low of $17.54 and a 12 month high of $30.15. The stock’s 50-day moving average is $20.24 and its two-hundred day moving average is $21.49. The stock has a market cap of $2.10 billion, a PE ratio of 93.11, a P/E/G ratio of 2.53 and a beta of 0.81.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The company had revenue of $440.80 million for the quarter, compared to analyst estimates of $425.81 million. During the same period last year, the firm posted $0.14 earnings per share. The business’s revenue was up 21.0% on a year-over-year basis. On average, research analysts anticipate that Privia Health Group, Inc. will post 0.26 earnings per share for the current year.

Insider Activity at Privia Health Group

In other Privia Health Group news, Director William M. Sullivan sold 9,951 shares of the business’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $23.03, for a total value of $229,171.53. Following the transaction, the director now owns 5,464,533 shares in the company, valued at approximately $125,848,194.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Privia Health Group news, Director William M. Sullivan sold 9,951 shares of Privia Health Group stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $23.03, for a total transaction of $229,171.53. Following the sale, the director now directly owns 5,464,533 shares in the company, valued at approximately $125,848,194.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO David Mountcastle sold 3,933 shares of the company’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total value of $69,889.41. Following the completion of the transaction, the chief financial officer now directly owns 262,279 shares in the company, valued at $4,660,697.83. The disclosure for this sale can be found here. Company insiders own 14.20% of the company’s stock.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.